OTCMKTS:PRTX Protalex - PRTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Protalex, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.01 0.00 (0.00%) (As of 06/25/2021) Add Compare Share Share Today's Range$0.0130▼$0.013050-Day Range$0.0130▼$0.013052-Week Range$0.00▼$0.10VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsFinancialsInsider TradesSEC FilingsShort Interest About Protalex (OTCMKTS:PRTX) StockProtalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.Read More Receive PRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalex and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTX Stock News HeadlinesJuly 14, 2021 | marketwatch.comMyasthenia Gravis - Pipeline Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2021-2028July 13, 2021 | marketwatch.comMyasthenia Gravis - Competitive Market Research Report with Size, Share, Value, CAGR, Outlook, Analysis, Latest Updates, Data, and News 2021-2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive PRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Protalex and its competitors with MarketBeat's FREE daily newsletter. Email Address PRTX Company Calendar Last Earnings4/13/2018Today2/05/2023Fiscal Year End5/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Commercial physical research Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:PRTX Previous SymbolNASDAQ:PRTX CUSIPN/A CIK1099215 Webwww.protalex.com Phone215-862-9720Fax215-862-6614Employees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesMr. Arnold P. Kling Esq. (Age 63)Pres & Director Comp: $72kDr. William E. Gannon Jr.Chief Medical Officer & Member of Scientific Advisory BoardDr. John Bruce Lundy McClain M.D.Medical Director & Member of Scientific Advisory BoardDr. Michelle Catalina Ph.D.Director of Preclinical Studies & Member of Scientific Advisory BoardKey CompetitorsAffinity Energy and HealthOTCMKTS:ALGXYDeltagenOTCMKTS:DGENRedpoint BioOTCMKTS:RPBC[email protected] TechnologyOTCMKTS:LPTC1933 IndustriesOTCMKTS:TGIFFView All Competitors PRTX Stock - Frequently Asked Questions How have PRTX shares performed in 2023? Protalex's stock was trading at $0.0130 at the beginning of 2023. Since then, PRTX stock has increased by 0.0% and is now trading at $0.0130. View the best growth stocks for 2023 here. How were Protalex's earnings last quarter? Protalex, Inc. (OTCMKTS:PRTX) posted its quarterly earnings results on Friday, April, 13th. The company reported ($0.06) EPS for the quarter. What other stocks do shareholders of Protalex own? Based on aggregate information from My MarketBeat watchlists, some companies that other Protalex investors own include Boeing (BA), Caterpillar (CAT), Salesforce (CRM), Enterprise Products Partners (EPD), Eros STX Global (EROS), Global Payments (GPN), Intuitive Surgical (ISRG), NVIDIA (NVDA), AT&T (T) and VirTra (VTSI). What is Protalex's stock symbol? Protalex trades on the OTCMKTS under the ticker symbol "PRTX." How do I buy shares of Protalex? Shares of PRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Protalex's stock price today? One share of PRTX stock can currently be purchased for approximately $0.01. How can I contact Protalex? Protalex's mailing address is 131 COLUMBIA TURNPIKE SUITE 1, FLORHAM PARK NJ, 07932. The official website for the company is www.protalex.com. The company can be reached via phone at 215-862-9720, via email at afields@lhai.com, or via fax at 215-862-6614. This page (OTCMKTS:PRTX) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.